Summary

The global CAR T-Cell Therapy market size was US$ 5417 million in 2024 and is forecast to a readjusted size of US$ 26750 million by 2031 with a CAGR of 26.0% during the forecast period 2025-2031.
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative form of immunotherapy that involves genetically modifying a patient’s own T cells to express a specific chimeric antigen receptor (CAR) on their surface. This receptor enables the T cells to target and destroy cancer cells effectively. CAR-T therapy has shown significant success in treating hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphomas, and is being explored for its potential applications in solid tumors.

The CAR-T Cell Therapy market is primarily driven by its groundbreaking effectiveness in treating certain types of hematological malignancies, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), particularly in patients who are refractory to standard treatments. The rising incidence of cancer globally and the growing demand for personalized and targeted therapies have further fueled market growth. In addition, advancements in genetic engineering and manufacturing processes are making CAR-T therapies safer, more efficient, and increasingly accessible. The strong support from government initiatives and private investments in oncology research is also accelerating the development of next-generation CAR-T products, expanding their therapeutic potential to include solid tumors.However, the market faces significant challenges, including the high cost of CAR-T therapies, which can exceed hundreds of thousands of dollars per treatment, making it inaccessible to many patients. The complex and time-consuming manufacturing process, which involves extracting and engineering a patient’s T cells, further contributes to these high costs. Additionally, CAR-T therapy is associated with severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, which require specialized management and can limit its broader adoption. Regulatory hurdles and the need for improved scalability also present obstacles, particularly in developing regions where healthcare infrastructure may be inadequate to support this advanced therapy.

The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.
The global CAR T-Cell Therapy market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

Market Segmentation
By Company:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
By Type: (Dominant Segment vs High-Margin Innovation)
CD19 - Targeted
BCMA - Targeted
By Application: (Core Demand Driver vs Emerging Opportunity)
Lymphoma
Multiple Myeloma
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Novartis in Europe)
- Emerging Product Trends: CD19 - Targeted adoption vs. BCMA - Targeted premiumization
- Demand-Side Dynamics: Lymphoma growth in China vs. Multiple Myeloma potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)

Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of CAR T-Cell Therapy market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., BCMA - Targeted in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Multiple Myeloma in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the CAR T-Cell Therapy value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 CD19 - Targeted
1.2.3 BCMA - Targeted
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global CAR T-Cell Therapy Revenue Market Share by Region (2020-2025)
2.4 Global CAR T-Cell Therapy Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America CAR T-Cell Therapy Market Size and Prospective (2020-2031)
2.5.2 Europe CAR T-Cell Therapy Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific CAR T-Cell Therapy Market Size and Prospective (2020-2031)
2.5.4 Latin America CAR T-Cell Therapy Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa CAR T-Cell Therapy Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global CAR T-Cell Therapy Historic Market Size by Type (2020-2025)
3.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2026-2031)
3.3 Different Types CAR T-Cell Therapy Representative Players
4 Breakdown Data by Application
4.1 Global CAR T-Cell Therapy Historic Market Size by Application (2020-2025)
4.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in CAR T-Cell Therapy Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2020-2025)
5.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by CAR T-Cell Therapy Revenue
5.4 Global CAR T-Cell Therapy Market Concentration Analysis
5.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Revenue in 2024
5.5 Global Key Players of CAR T-Cell Therapy Head office and Area Served
5.6 Global Key Players of CAR T-Cell Therapy, Product and Application
5.7 Global Key Players of CAR T-Cell Therapy, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America CAR T-Cell Therapy Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America CAR T-Cell Therapy Market Size by Type (2020-2025)
6.1.2.2 North America CAR T-Cell Therapy Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America CAR T-Cell Therapy Market Size by Application (2020-2025)
6.1.3.2 North America CAR T-Cell Therapy Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe CAR T-Cell Therapy Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe CAR T-Cell Therapy Market Size by Type (2020-2025)
6.2.2.2 Europe CAR T-Cell Therapy Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe CAR T-Cell Therapy Market Size by Application (2020-2025)
6.2.3.2 Europe CAR T-Cell Therapy Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific CAR T-Cell Therapy Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific CAR T-Cell Therapy Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific CAR T-Cell Therapy Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific CAR T-Cell Therapy Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific CAR T-Cell Therapy Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America CAR T-Cell Therapy Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America CAR T-Cell Therapy Market Size by Type (2020-2025)
6.4.2.2 Latin America CAR T-Cell Therapy Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America CAR T-Cell Therapy Market Size by Application (2020-2025)
6.4.3.2 Latin America CAR T-Cell Therapy Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa CAR T-Cell Therapy Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa CAR T-Cell Therapy Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa CAR T-Cell Therapy Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa CAR T-Cell Therapy Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa CAR T-Cell Therapy Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Novartis
7.1.1 Novartis Company Details
7.1.2 Novartis Business Overview
7.1.3 Novartis CAR T-Cell Therapy Introduction
7.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2020-2025)
7.1.5 Novartis Recent Development
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Details
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences CAR T-Cell Therapy Introduction
7.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2020-2025)
7.2.5 Gilead Sciences Recent Development
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Company Details
7.3.2 Bristol-Myers Squibb Business Overview
7.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction
7.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2020-2025)
7.3.5 Bristol-Myers Squibb Recent Development
7.4 J & J
7.4.1 J & J Company Details
7.4.2 J & J Business Overview
7.4.3 J & J CAR T-Cell Therapy Introduction
7.4.4 J & J Revenue in CAR T-Cell Therapy Business (2020-2025)
7.4.5 J & J Recent Development
7.5 JW Therapeutics
7.5.1 JW Therapeutics Company Details
7.5.2 JW Therapeutics Business Overview
7.5.3 JW Therapeutics CAR T-Cell Therapy Introduction
7.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2020-2025)
7.5.5 JW Therapeutics Recent Development
7.6 FOSUNKite
7.6.1 FOSUNKite Company Details
7.6.2 FOSUNKite Business Overview
7.6.3 FOSUNKite CAR T-Cell Therapy Introduction
7.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2020-2025)
7.6.5 FOSUNKite Recent Development
7.7 CARsgen Therapeutics (Pipeline)
7.7.1 CARsgen Therapeutics (Pipeline) Company Details
7.7.2 CARsgen Therapeutics (Pipeline) Business Overview
7.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Introduction
7.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.7.5 CARsgen Therapeutics (Pipeline) Recent Development
7.8 Autolus Therapeutics(Pipeline)
7.8.1 Autolus Therapeutics(Pipeline) Company Details
7.8.2 Autolus Therapeutics(Pipeline) Business Overview
7.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
7.8.4 Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.8.5 Autolus Therapeutics(Pipeline) Recent Development
7.9 Sorrento Therapeutics(Pipeline)
7.9.1 Sorrento Therapeutics(Pipeline) Company Details
7.9.2 Sorrento Therapeutics(Pipeline) Business Overview
7.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
7.9.4 Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.9.5 Sorrento Therapeutics(Pipeline) Recent Development
7.10 Mustang Bio(Pipeline)
7.10.1 Mustang Bio(Pipeline) Company Details
7.10.2 Mustang Bio(Pipeline) Business Overview
7.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Introduction
7.10.4 Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.10.5 Mustang Bio(Pipeline) Recent Development
7.11 Bluebird Bio(Pipeline)
7.11.1 Bluebird Bio(Pipeline) Company Details
7.11.2 Bluebird Bio(Pipeline) Business Overview
7.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Introduction
7.11.4 Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.11.5 Bluebird Bio(Pipeline) Recent Development
7.12 Cellectis(Pipeline)
7.12.1 Cellectis(Pipeline) Company Details
7.12.2 Cellectis(Pipeline) Business Overview
7.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Introduction
7.12.4 Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.12.5 Cellectis(Pipeline) Recent Development
7.13 Allogene Therapeutics(Pipeline)
7.13.1 Allogene Therapeutics(Pipeline) Company Details
7.13.2 Allogene Therapeutics(Pipeline) Business Overview
7.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
7.13.4 Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.13.5 Allogene Therapeutics(Pipeline) Recent Development
7.14 Celyad(Pipeline)
7.14.1 Celyad(Pipeline) Company Details
7.14.2 Celyad(Pipeline) Business Overview
7.14.3 Celyad(Pipeline) CAR T-Cell Therapy Introduction
7.14.4 Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)
7.14.5 Celyad(Pipeline) Recent Development
8 CAR T-Cell Therapy Market Dynamics
8.1 CAR T-Cell Therapy Industry Trends
8.2 CAR T-Cell Therapy Market Drivers
8.3 CAR T-Cell Therapy Market Challenges
8.4 CAR T-Cell Therapy Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer